Prognostic Impact of Postoperative C-Reactive Protein Level in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy

Journal of Urology

Volumn 180, Issue 2, 2008, Pages 515-519

  Tatokoro, Manabu ^a   Saito, Kazutaka ^a   Iimura, Yasumasa ^a   Fujii, Yasuhisa ^a   Kawakami, Satoru ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

C reactive protein; carcinoma, renal cell; nephrectomy; postoperative period; prognosis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COURSE EVALUATION; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 46449103728     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.04.025     Document Type: Article

References (20)

1. Vogl U.M., Zehetgruber H., Dominkus M., Hejna M., Zielinski C.C., Haitel A., et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 95 (2006) 691
2. Bleumer I., Oosterwijk E., De Mulder P., and Mulders P.F. Immunotherapy for renal cell carcinoma. Eur Urol 44 (2003) 65
3. Motzer R.J., Bacik J., Schwartz L.H., Reuter V., Russo P., Marion S., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454
4. Atzpodien J., Royston P., Wandert T., and Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88 (1999) 348
5. Rini B.I., and Campbell S.C. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 177 (2007) 1978
6. Flanigan R.C., Mickisch G., Sylvester R., Tangen C., Van Poppel H., and Crawford E.D. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171 (2004) 1071
7. Saito K., Kawakami S., Ohtsuka Y., Fujii Y., Masuda H., Kumagai J., et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 100 (2007) 269
8. Komai Y., Saito K., Sakai K., and Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 99 (2007) 77
9. Lamb G.W., McMillan D.C., Ramsey S., and Aitchison M. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer 94 (2006) 781
10. Ito K., Asano T., Yoshii H., Satoh A., Sumitomo M., and Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 13 (2006) 1365
11. Karakiewicz P.I., Hutterer G.C., Trinh Q.D., Jeldres C., Perrotte P., Gallina A., et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110 (2007) 1241
12. Casamassima A., Picciariello M., Quaranta M., Berardino R., Ranieri C., Paradiso A., et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 173 (2005) 52
13. Ramsey S., Lamb G.W., Aitchison M., Graham J., and McMillan D.C. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109 (2007) 205
14. Yoshida S., Saito K., Koga F., Yokoyama M., Kageyama Y., Masuda H., et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemotherapy. BJU Int 101 (2008) 10
15. Fujikawa K., Matsui Y., Oka H., Fukuzawa S., and Takeuchi H. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol 162 (1999) 1934
16. Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., Haller D.G., et al. Part IX-Genitourinary Sites. AJCC Cancer Staging Manual. 6th ed. (2002), Springer-Verlag, New York 323-328
17. Mostofi F., and Davis C. Histological Classification of Kidney Tumors (1988), Springer, Berlin
18. Miki S., Iwano M., Miki Y., Yamamoto M., Tang B., Yokokawa K., et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250 (1989) 607
19. Koo A.S., Armstrong C., Bochner B., Shimabukuro T., Tso C.L., deKernion J.B., et al. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother 35 (1992) 97
20. Nieken J., Mulder N.H., Buter J., Vellenga E., Limburg P.C., Piers D.A., et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 86 (1995) 900